Pharming N.V.(PHAR) - 2024 Q4 - Annual Report

Form 6-K Report of Foreign Private Issuer (April 2025) This Form 6-K report provides key announcements from a foreign private issuer in April 2025 Announcement of 2024 Annual Report and Form 20-F Filing Pharming Group N.V. announced the filing of its Annual Report for the year ended December 31, 2024, along with its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) - Pharming Group N.V. has filed its Annual Report for the year ended December 31, 2024[8] - The company also filed its Annual Report on Form 20-F with the U.S. SEC for the same period[9] - The reports are available on the Pharming.com website under the 'Investors' section and through the SEC website[8][9] About Pharming Group N.V. Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands, focusing on innovative medicines for rare and life-threatening diseases across over 30 markets - Pharming is a global biopharmaceutical company dedicated to treating patients with rare, debilitating, and life-threatening diseases[10] - The company's portfolio includes commercialized and developing innovative medicines, such as small molecules and biologics[10] - Headquartered in Leiden, the Netherlands, Pharming serves patients in over 30 markets worldwide[10] Other Information This section discloses that the press release content may qualify as inside information under EU Market Abuse Regulation and provides contact details for investor and public relations - The press release may contain information that qualifies as 'inside information' within the meaning of Article 7(1) of the EU Market Abuse Regulation[12] - Contact details for investor relations, corporate communications, and public relations are provided for further inquiries[13]